Cancer Vaccine Comeback: Data Boost Antigenics and Others

Cancer vaccines are back in fashion, thanks to Dendreon Corp.'s recent Phase III success with Provenge (sipuleucel-T) in prostate cancer, and encouraging data presented this weekend at the American Society of Clinical Oncology's annual meeting sent shares of several other cancer vaccine players skyrocketing. (BioWorld Today)